Cargando…
The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth
PURPOSE: Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERα)-negative disease, and decreased preclinical mammary tumor growth...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394576/ https://www.ncbi.nlm.nih.gov/pubmed/30367332 http://dx.doi.org/10.1007/s10549-018-5021-6 |
_version_ | 1783398926476378112 |
---|---|
author | Bowers, Laura W. Lineberger, Claire G. Ford, Nikki A. Rossi, Emily L. Punjala, Arunima Camp, Kristina K. Kimler, Bruce K. Fabian, Carol J. Hursting, Stephen D. |
author_facet | Bowers, Laura W. Lineberger, Claire G. Ford, Nikki A. Rossi, Emily L. Punjala, Arunima Camp, Kristina K. Kimler, Bruce K. Fabian, Carol J. Hursting, Stephen D. |
author_sort | Bowers, Laura W. |
collection | PubMed |
description | PURPOSE: Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERα)-negative disease, and decreased preclinical mammary tumor growth. However, while preclinical studies have established that SDG and ENL affect measures of progression in models of triple-negative breast cancer (TNBC, a subset of ERα-negative disease), the molecular mechanisms underlying these effects remain unclear. METHODS: C57BL/6 mice were fed a control diet (control, 10% kcal from fat) or control diet + SDG (SDG, 100 mg/kg diet) for 8 weeks, then orthotopically injected with syngeneic E0771 mammary tumor cells (a model of TNBC); tumor growth was monitored for 3 weeks. The role of reduced NF-κB signaling in SDG’s anti-tumor effects was explored in vitro via treatment with the bioactive SDG metabolite ENL. In addition to the murine E0771 cells, the in vitro studies utilized MDA-MB-231 and MCF-7 cells, two human cell lines which model the triple-negative and luminal A breast cancer subtypes, respectively. RESULTS: SDG supplementation in the mice significantly reduced tumor volume and expression of phospho-p65 and NF-κB target genes (P < 0.05). Markers of macrophage infiltration were decreased in the distal-to-tumor mammary fat pad of mice supplemented with SDG relative to control mice (P < 0.05). In vitro, ENL treatment inhibited viability, survival, and NF-κB activity and target gene expression in E0771, MDA-MB-231, and MCF-7 cells (P < 0.05). Overexpression of Rela attenuated ENL’s inhibition of E0771 cell viability and survival. CONCLUSIONS: SDG reduces tumor growth in the E0771 model of TNBC, likely via a mechanism involving inhibition of NF-κB activity. SDG could serve as a practical and effective adjuvant treatment to reduce recurrence, but greater understanding of its effects is needed to inform the development of more targeted recommendations for its use. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-018-5021-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6394576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-63945762019-03-15 The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth Bowers, Laura W. Lineberger, Claire G. Ford, Nikki A. Rossi, Emily L. Punjala, Arunima Camp, Kristina K. Kimler, Bruce K. Fabian, Carol J. Hursting, Stephen D. Breast Cancer Res Treat Preclinical Study PURPOSE: Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERα)-negative disease, and decreased preclinical mammary tumor growth. However, while preclinical studies have established that SDG and ENL affect measures of progression in models of triple-negative breast cancer (TNBC, a subset of ERα-negative disease), the molecular mechanisms underlying these effects remain unclear. METHODS: C57BL/6 mice were fed a control diet (control, 10% kcal from fat) or control diet + SDG (SDG, 100 mg/kg diet) for 8 weeks, then orthotopically injected with syngeneic E0771 mammary tumor cells (a model of TNBC); tumor growth was monitored for 3 weeks. The role of reduced NF-κB signaling in SDG’s anti-tumor effects was explored in vitro via treatment with the bioactive SDG metabolite ENL. In addition to the murine E0771 cells, the in vitro studies utilized MDA-MB-231 and MCF-7 cells, two human cell lines which model the triple-negative and luminal A breast cancer subtypes, respectively. RESULTS: SDG supplementation in the mice significantly reduced tumor volume and expression of phospho-p65 and NF-κB target genes (P < 0.05). Markers of macrophage infiltration were decreased in the distal-to-tumor mammary fat pad of mice supplemented with SDG relative to control mice (P < 0.05). In vitro, ENL treatment inhibited viability, survival, and NF-κB activity and target gene expression in E0771, MDA-MB-231, and MCF-7 cells (P < 0.05). Overexpression of Rela attenuated ENL’s inhibition of E0771 cell viability and survival. CONCLUSIONS: SDG reduces tumor growth in the E0771 model of TNBC, likely via a mechanism involving inhibition of NF-κB activity. SDG could serve as a practical and effective adjuvant treatment to reduce recurrence, but greater understanding of its effects is needed to inform the development of more targeted recommendations for its use. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-018-5021-6) contains supplementary material, which is available to authorized users. Springer US 2018-10-26 2019 /pmc/articles/PMC6394576/ /pubmed/30367332 http://dx.doi.org/10.1007/s10549-018-5021-6 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Preclinical Study Bowers, Laura W. Lineberger, Claire G. Ford, Nikki A. Rossi, Emily L. Punjala, Arunima Camp, Kristina K. Kimler, Bruce K. Fabian, Carol J. Hursting, Stephen D. The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth |
title | The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth |
title_full | The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth |
title_fullStr | The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth |
title_full_unstemmed | The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth |
title_short | The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth |
title_sort | flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses nfκb signaling, and inhibits mammary tumor growth |
topic | Preclinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394576/ https://www.ncbi.nlm.nih.gov/pubmed/30367332 http://dx.doi.org/10.1007/s10549-018-5021-6 |
work_keys_str_mv | AT bowerslauraw theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT linebergerclaireg theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT fordnikkia theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT rossiemilyl theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT punjalaarunima theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT campkristinak theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT kimlerbrucek theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT fabiancarolj theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT hurstingstephend theflaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT bowerslauraw flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT linebergerclaireg flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT fordnikkia flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT rossiemilyl flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT punjalaarunima flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT campkristinak flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT kimlerbrucek flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT fabiancarolj flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth AT hurstingstephend flaxseedlignansecoisolariciresinoldiglucosidedecreaseslocalinflammationsuppressesnfkbsignalingandinhibitsmammarytumorgrowth |